ArticleCureus2025
Expanding the Spectrum of Charles Bonnet Syndrome: Severe Psychiatric Manifestations Associated With Total Vision Loss.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Charles Bonnet syndrome (CBS) is typically characterized by complex, non-threatening visual hallucinations in patients with visual impairment who maintain insight that their perceptions are unreal. While primarily considered an ophthalmological phenomenon, recent evidence suggests that CBS may overlap with psychiatric disorders presenting with complex visual hallucinations and impaired insight, complicating both diagnosis and management. These interactions challenge the view of CBS as a benign and isolated condition, especially when symptoms become more entrenched, resemble psychosis, or co-occur with pre-existing psychiatric disorders. We present a new, atypical case involving a patient with CBS and evolving psychotic symptoms at the Olive View Medical Center in California. Our case highlights a 40-year-old female patient with bilateral blindness and a history of CBS, schizoaffective disorder, and repeated Lanterman-Petris-Short conservatorships. At presentation, she exhibited aggressive behavior, possible delusions, responses to internal stimuli, and significant difficulties in self-care. Treatment included a regimen of olanzapine (25 mg daily), haloperidol (15 mg daily), gabapentin (1800 mg daily), hydroxyzine (150 mg daily), and divalproex sodium (2000 mg daily), resulting in some symptom amelioration but persistent psychotic features. The patient's ongoing conservatorship demonstrates the severity and chronicity of her condition. This case suggests that even in patients with total vision loss, CBS has the potential to evolve beyond isolated visual hallucinations to include severe psychiatric sequelae, including psychotic symptoms. These findings call for greater clinical vigilance, timely ophthalmologic and psychiatric consultation, and interdisciplinary management. Further research is needed to elucidate the neurobiological mechanisms linking sensory deprivation to complex hallucinations and psychiatric disturbances. An improved understanding of these processes may guide more accurate diagnostics and inform targeted interventions, ultimately improving outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.